A Risk-Based Approach to Pharmaceutical Current
Good Manufacturing Practices (cGMP) for the 21^st Century

Previous Reports, Guidances and Additional Information

Second Progress Report and Implementation Plan, September 2003

• FDA Press Release (issued September 3, 2003)
• Pharmaceutical cGMPs for the 21st Century — A Risk-Based Approach:  Second Progress Report and Implementation Plan (issued September 3, 2003)
  
• International Conference on Harmonisation (ICH) Press Release: "Step 4 for the ICH6 Program" (Brussels, Belgium, Europe, July 17-18, 2003)
• Material Transfer Agreement (MTA) [PDF]
• Memorandum of Understanding (MOU) between the Office of Regulatory Affairs and the Center for Drug Evaluation and Research on the Pharmaceutical Inspectorate [PDF]
  • Pharmaceutical Inspectorate:  Questions and Answers (revised January 2004, posted April 13, 2004)
• Potential Use of Specialists — An Emerging Team Approach [PDF]
• Preapproval Inspections (Compliance Program #7346.832) [PDF] 

Guidances

• FDA Takes First Step in Recognizing the Role of Emerging Technologies in the Area of Process Validation  (posted March 17, 2004)
• Part 11, Electronic Records, Electronic Signatures — Scope and Application (final guidance) [HTML]   Optional formats: [PDF] [Word] (posted 9/3/2003)
• Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP (draft guidance) [HTML]   Optional formats: [PDF]  [Word] (posted 9/3/2003)
• Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice [HTML] [PDF] [Word] Posted 9/29/2004
• Comparability Protocols — Protein Drug Products and Biological Products, Chemistry, Manufacturing, and Controls Information (draft guidance) [PDF]  [Word] (posted 9/3/2003)
• PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance [HTML] [PDF] [Word] (posted 9/29/2004)
  
• FR Notice of Availability--Draft Guidance for Industry on Part 11, Electronic Records, Electronic Signatures--Scope and Application  
• Draft Guidance for Industry on Part 11, Electronic Records, Electronic Signatures--Scope and Application  
• FR Notice of Availability--Draft Guidance for Industry on Comparability Protocols Small Molecules  
• Draft Guidance for Industry on Comparability Protocols Small Molecules  

cGMP Implementation

• Drug GMP Task Groups
  • Pharmaceutical Working Groups
  • Steering Committee
  • Individual Task Group Membership

Task Group Progress Reports (February 2003)

• Report on Process Analytical Technology
• Report of the 483 Communications Working Group
• Proposed Process for Dispute Resolution
• Report of the Pharmaceutical Inspectorate Working Group
• Report of the Product Specialists on Inspection Teams Working Group
• Report on Effective Business Practices and Policies in Other Organizations

Public Feedback

• Make Public Comments to the Docket:
• General cGMP Comments Electronic Docket: Comment Form
• Comments on the Draft Guidance for Industry on Part 11, Electronic Records, Electronic Signatures--Scope and Application: Comment Form
• Comments on the Draft Guidance for Industry on Comparability Protocols Small Molecules: Comment Form
• Read Public Comments to the Docket:
• General cGMP Comments Electronic Docket

• Workshop Information, including Background, Final Agenda and Breakout Session Topics.  Cosponsored by the Product Quality Research Institute (PQRI) and the Food and Drug Administration (updated 4/16/2003)
• Workshop Summary

FDA’s Pharmaceutical Quality Initiatives – Implementation of a Modern Risk-Based Approach, February 28 to March 2, 2007, Bethesda, Maryland

• Workshop Information (7/28/2006)

Other Reports and Announcements

• Progress Report, February 20, 2003
• FDA Press Release
• Summary Progress Report
• Questions and Answers

• FDA, GMP Initiative Announcement, August 21, 2002 
• FDA Press Release
• Risk-based Approach Concept Paper
• Questions and Answers

Back to Top     Final cGMP's Report

Date created: February 27, 2003; Last Updated: July 28, 2006

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research